XXXX Great. good and customers, marks strong execution growth Thank for We and with another our create Fiscal you, of Brian, performance. financial fiscal XXXX momentum year and value afternoon, deliver entered partners to shareholders. everyone. the and
overview our discuss XXXX refer comments state provide today outlook. XXXX year otherwise. will full I'll quarter My fourth our unless Today, fiscal our Then I fiscal to adjusted I'll and results. an results of
fiscal XXXX for the fourth exiting full $XX.XX We're the quarter $X.XX earnings share delivering with per and performance, in of diluted year. solid
range quarter that create in quarter our against sustainable fourth provided shareholders. the Our and results company call, for we execute on share with to long-term ability third our consistently diluted guidance with demonstrating priorities earnings earnings line value our our per were and expectations
excluding and of execution. adjusted our and the EPS XX%. products, targets long-range when X% increased programs year, reflect XXXX strength These and our full COVID-related grew the contributions above operating operating For and results are profit adjusted from fiscal services McKesson Ventures,
segment, Pharmaceutical review with the U.S. a from volumes, $XX.X billion, fiscal resulting volumes by quarter. increased medications. retail to customers fourth start prescription XX% from higher products, in me GLP-X growth specialty increased national Let of including account Revenues and led the
of and growth billion Operating Gross costs to the $X.X increase of and within to result segment, driven profit Pharmaceutical biologics increased support was $X.X U.S. X% primarily higher billion, growth the distribution specialty including business. our an leading plasma XX% by a businesses. expenses across
we we ago. disposed of for of related per quarter, for matters costs the environmental chemical to reserve McKesson's several remediation years $X.XX recorded which During increased former a share business
Pharmaceutical in programs The offset flat anticipated when in expenses, outlined COVID-XX our Operating previously Pharmaceutical to U.S. by to corporate included impacted which prior Medical segment, also both $X.X were growth year corporate was increased Surgical environmental by and the recorded by from Solutions the results was reserve environmental segments prior billion, the compared Year-over-year was in profit year. segment. lower the government driven U.S. reserve. the which contributions U.S.
fiscal increased adjusted COVID-XX the in programs XXXX, quarter. a McKesson the modest profit X% for and adjusting operating Ventures When in loss
was higher Moving line. compared to $XX increase the driven Interest of the X%, an prior commercial of below short-term borrowings expense year. million, paper by
balances borrowings our by to item. resulted driven short-term discrete part in from cash previous outage. due for higher average tax line and XX.X%, was the quarter impact Healthcare the The the in guidance with tax from Change rate The effective a is lower which
third our of $X.XX, X% again, outstanding Fourth with weighted share per Wrapping shares call. share was the million, in we quarter provided up average decrease consolidated our year-over-year. that diluted diluted earnings results, quarter $XXX.X line Earnings implied per earnings on was a diluted
a growth were While a program partially year, Pharmaceutical offset of share in contributions a XXXX, tax XX% results U.S. to prior fiscal COVID-XX higher driven compared segment. quarter decrease and this rate by and the lower count by lower fourth principally represents in
Turning results, and found quarter now can be U.S. which to through segment our Slides starting on fourth XX with Pharmaceutical. X
national volumes, including specialty XX% products, increased prescription $XX.X account Revenues were and retail higher an billion, customers and driven volumes increase medications. from by of GLP-X
were we the this of fiscal approximately continue an despite continues quarter, have medications rate to previously $X.X to In GLP-X growth XX% billion, increase, growth GLP-X the revenues As or billion moderate. show but compared guided, of to year-over-year increase $X.X XXXX.
revenues were sequential flat basis. However, GLP-X a on
to For continued stakeholders. contributions the increased from profit operating and to providers capabilities growth to breadth our to program. in systems $XXX the quarter, million by deliver products health X% distribution and assets generics specialty our driven value and The increased robust of of
Solutions which were were Our prior primarily services solutions. contributions offset Prescription access and technology to billion, Technology segment, our revenues from our business by the Lower products $X.X the logistics year. growth third-party flat across were
Results are organic and workflows. and including the we partners connectivity biopharma reflect CoverMyMeds value prior services extended through partnerships across with for Within by access in and providers, solutions automated payers affordability that continues authorization manufacturers our to deliver existing growth access, into quarter our integrated manufacturers. pharmacies, segment, this as provider biopharma next-generation increasing fourth between adherence solutions,
In costs to of customers. and profit deliver performance for investments across access of by to biopharma million, momentum services decreased platform. the This addition solutions, to X% investments sustain infrastructure year-over-year higher levels solutions. driven cost included $XXX also the affordability ROI our higher the and growth across and increasing to supported was Operating our incremental our volumes strength by
lower Operating compared in logistics profit by to prior the year. was impacted the also quarter third-party performance
illness Fourth million, to quarter COVID-XX profit the to contributions from distribution government's was growth the increase were in season and versus and an businesses, year. Care Solutions. partially year. including of Extended kitting $X.X was Revenues the ancillary reflect program billion, supplies prior Turning $XXX prior higher Primary X% results of by testing, volumes and flat the Medical-Surgical the Care offset lower storage of operating U.S. compared for which
the respiratory illness onset reminder, of on severity that is season and As a each during unique depending illnesses various year. particular
results. increase by and an higher driven our Next, prior the million, international the Revenues distribution were was an operating let $X.X strong These billion, business to $XX XX%. were of me address profit year. of pharmaceutical Canadian X% increase in volumes compared results
review. expenses of were the discussed and million Wrapping reserve quarter, XX%, an increase previously in infrastructure driven compliance up our spend. environmental segment higher $XXX Corporate and the technology by
equivalents. We cash in can the be Let deployment, quarter found turn me $X.X now to on capital Slide XX. with cash and which billion ended and cash
the we including $X.X analytics For and and $XXX data in generated investments flow, billion million as in fiscal free well our which capital cash expenditures, to existing of year, growth new included distribution priorities. centers support technology, as
quarter, customers billing Change delaying and timing impact flows. a impacted Healthcare claims the were During outage, by outage several cash payments. McKesson's created the of our This functions on
impact the previously than less However, was had severe indicated. we
approximately $X billion price $XXX $XXX [ million quarter. capital share our deployment XXXX, fiscal value for We We of of shareholders. continue share to on to fiscal the in to including share focus an fourth returned returned stakeholders. we $X.X drive In average at repurchases per billion cash of repurchases through ],
dividends repurchases year. free XXXX. paid of flow paid, share billion cash the When Since $XXX fiscal share we repurchases XX% dividends we for $XX.X returned beginning of with we shareholders shareholders full returned to Additionally, and XXXX, through have of combining dividends. of cash fiscal in approximately the to million
balanced repurchases, upgrade share The reducing amount, credit BAAX. returned sheet and was strength in Moody's credit approximately shares quarter our our and operating to been $XX.X from outstanding recognized by strong AX the policy billion through balance metrics, performance nearly the Of and rating XX%. by financial supported strong average recent this our has total by disciplined of
major of the agencies. X We credit rating A now rated X are by
capital robust sheet strategic continues return to in capital flow Our a pursue while generation, provide strong our us all invest disciplined along to and consistently cash balance the with flexibility opportunities allocation with to durable shareholders, capital financial and maintaining structure. initiatives, growth
our partners of have capabilities outlook. portfolio XXXX X customers, creation and breadth services, last the discuss over assets The and value leading biopharma shareholders for led across to Now years. fiscal our let of oncology me and our
continuation of outlook a XXXX this momentum. fiscal is Our
with sustainable and X% XX% business start to me U.S. revenues operating profit to and to and increase our propelled anticipate platform. growth oncology in the momentum across increase segments. Let XX% our distribution core by to We XX% pharmaceutical
We more our partnership distribution core existing make network contract continue This deliver to X-year efficiency to highlighted the distribution on stakeholders. recent X, investments Optum. value with our XXXX. in value build the for agreement our and to proposition strength of on July was begins pharmaceutical The by
utilization leading segment generic breadth business. Institute the prescription platform outlook specialty the through and venture. growing our anticipate our our Cannon distribution, fiscal from Oncology sourcing further stable, and and We in Ontada XXXX programs Network, The growth differentiated assets, trends, biologics growth U.S. by further bolstered Research incorporates Sarah of plasma our oncology including joint
As oncology Brian our with X,XXX Sarah with states, care. supporting XX and advancements providers to U.S. Cannon and made the pleased mission in XXXX, Ontada Research the cancer mentioned, as of we've grown network approximately advance we're April has to Institute
We are oncology pleased growth and seeing segment we're the assets our U.S. and platform to as core in growth. Pharmaceutical the distribution accelerate and the continued with capabilities
brands manufacturers GLP-X affordability and we segment, for to XX% increase medications. the outlook with we reflects and and utilizing and XX% those to number profit continue XX%. access, expand increase and to related access across see and programs. Technology to extend our XXXX, XX% operating revenues This Prescription increased services our fiscal adherence In growth organic demand of affordability biopharma to partnerships as the anticipate our particularly Throughout solutions, Solutions solutions we to increase
of majority the the serve products authorization prior GLP-X McKesson's brands medications. reminder, a As for
value generate partners. our to continue products for Our
will slower of will than as yet GLP-X for we to Looking demand medications. the lessen prior increase fiscal remain this be elevated, years anticipate XXXX, ahead that rate
leverage remains of assets and comprehensive breadth business well depth Medical-Surgical our of private growth its the positioned care in primary services alternate all care, and sites business to and portfolio. across the including label
We to revenues to X% increase anticipate X%. operating profit X% Solutions to increase to Medical-Surgical and X%
specialty solutions primary anticipate market, care growth lab we and pharmaceuticals. the in Within continued
McKesson. Our scale economics providing sourcing portfolio, customers. maintaining and and growth distribution our private propelled footprint while for our label for superior sound value has expansion of
In captures biopharma. fiscal a of that analytics platform provide this segment data in support XXXX, recent for we're Compile, the acquisition making health insights data care aggregates to and and to investments
use case Medical-Surgical an believe providers develop of value relationships extensive Solutions opportunities initial We the Medical-Surgical to has sets, incremental broad with segment and segment. there's The across Solutions the breadth creation data opportunities. meeting
Longer term, increased biopharma integrate in to deliver commercial services segment platforms. meaningful opportunities are to capabilities across the the will These there oncology our the investments returns to applications and enterprise. and
we these as medical account compared profit the will XXXX, operating headwind prior in fiscal to X% investments anticipate the In approximate an segment year. that for
to profit Finally, the to and increase X% to XX% X% International we anticipate operating X% year-over-year. increase segment, to revenues
Our the in diversified set business, including business, scale segment. Canadian assets continues of the to distribution within our growth International support
in continue and drugs. Canadian integrated create to more for technology chain a supply specialty to make investments footprint our We custom
reminder, in Norway operations to intend Norway the entered the that of exit Europe an part included country our only as operating in remains contributions for are a to related outlook completion the As We agreement we of the to exit. fiscal European Norway segment. XXXX into have and in sell not
growth million of to businesses expenses to segment, anticipate $XXX and and to support range million, technology investments. of which in In increased be the the our infrastructure the Corporate compliance spend includes $XXX we
data including continue also analytics, will to We investments intelligence. artificial acceleration in of several and invest the in
across for and our customers. increase leveraging productivity are efficiency operations AI to We automation our increase and the
provider an AI customer role improving play Our service and important investments and in productivity. in technologies advanced other
across increase continue to speed to and chain the success value rates. tools build We these
such extracted oncology The we're and sparsely entered documents capture One structured have condition as implementing on required database. treatment the iKnowMed data from records. to example research in core real-world to AI to response in for as are unstructured patients' are factors well-organized used where provider complete our can disease core data data to is patients' unstructured many into a EHR longitudinal authored be patient contains uploaded well that platform. for details notes, be often as records Instead, variables longitudinal clinical
and Natural than solution documents just patient documents and growing deliver scalable practice in per better The week. iKnowMed today and our million X in language is the where financial and achieve exhaustive one documents workflows, AI to the stakeholders. finding more using of process example at application to care of of XXX burden related care. reduces leading to we're to ultimately AI only for reimbursement million rate is many insights clinicians and efficiencies value clinical This power
our AI various our partners been We've date as technologies, increased investment leadership our remain work to further value to to and and we progress develop pleased to to committed implement with we and position and stakeholders. deliver extend
the tax the below And to to interest difficult a income to range the moving predict, timing tax anticipate to discrete of the full million year are attributable line. items provide rate XX% effective million $XXX effective $XXX reminder, expense tax in will $XXX amount to be and interest do quarterly therefore, We as and approximately we guidance. Now range to We approximately to million be anticipate million. noncontrolling not be $XXX rate of and in of the XX%.
deployment. capital approximately anticipate billion $X.X to Turning of We now and flow cash flow free billion. cash to $X.X
free Our impacted that resulting and the and quarter. from marks timing by day working a flow week the quarter-to-quarter vary cash metrics are including the of capital will of close
of plans guidance shares Our to in fiscal $X.X billion repurchase approximately reflects XXXX.
incrementally The both result flows as As well for to the as growth the our and activity, in return invest XXX million. inorganically to of we approximately range balance average sheet organically operating cash a diluted capital our shares repurchase of financial flexibility million the strength outstanding XXX of share weighted shareholders. provides to estimate and be to
anticipate growth XX% XX% We of an to X% to XXXX prior year. of profit operating fiscal growth up revenue and XX% Wrapping as the compared guidance. to
fiscal XX% compared share to diluted to to per which represents XX% of earnings anticipate XXXX. growth we XXXX, of fiscal $XX.XX For as $XX.XX,
of earnings more expect the weighted We half will second the heavily year. be fiscal towards share per
contribution. We quarter have lowest to the also anticipate the first
quarter reminder, we in to XXXX As a due effective item. fundamentals businesses. summary, a strength the in fiscal lower tax and first had underlying tax we across a the our see In rate of stability discrete
strength operating compelling sustained execution, performance our years to by several creation and Our has the and of bolstered financial past value leading our financial been position customers, for consistent over shareholders. the the partners,
pleased XXXX We're balance and XXXX continued in the strong with our the all the business, fiscal the and of fiscal profit momentum strong outlook the segments supplemented reflects by performance operating across confidence growth our position. sheet strength financial of
McKesson move is as strategic deliver we positioned can to strong results financial to stakeholders. to growth drive we for Q&A. successfully framework sustainable against With and that, our well execute long-term all
